middle.news

Mach7 Technologies Strengthens Position with Solid Q3 FY25 Results and CEO Transition

6:25am on Monday 2nd of June, 2025 AEST Healthcare Technology
Read Story

Mach7 Technologies Strengthens Position with Solid Q3 FY25 Results and CEO Transition

6:25am on Monday 2nd of June, 2025 AEST
Key Points
  • Contracted Annual Recurring Revenue (CARR) of A$30.8M as of 31 March 2025
  • Annual Recurring Revenue (ARR) run rate at A$24.4M, slight decrease due to customer shift
  • Positive operating cash flow of A$2.6M in Q3 and cash balance of A$24.9M with no debt
  • On-market share buy-back program commenced, acquiring 3.4M shares to date
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Mach7 Technologies (ASX:M7T)
OPEN ARTICLE